Share on StockTwits

Flamel Technologies S.A. (NASDAQ:FLML) was the recipient of a large decrease in short interest during the month of August. As of August 15th, there was short interest totalling 368,405 shares, a decrease of 48.8% from the July 31st total of 719,373 shares, ARN reports. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily volume of 228,299 shares, the short-interest ratio is currently 1.6 days.

A number of research firms have recently commented on FLML. Analysts at Zacks downgraded shares of Flamel Technologies S.A. from an “outperform” rating to a “neutral” rating in a research note on Wednesday, August 13th. They now have a $16.20 price target on the stock. Analysts at Leerink Swann initiated coverage on shares of Flamel Technologies S.A. in a research note on Friday, August 1st. They set an “outperform” rating and a $22.00 price target on the stock. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Flamel Technologies S.A. presently has a consensus rating of “Buy” and a consensus target price of $17.90.

Shares of Flamel Technologies S.A. (NASDAQ:FLML) opened at 14.15 on Thursday. Flamel Technologies S.A. has a 52 week low of $5.30 and a 52 week high of $15.96. The stock’s 50-day moving average is $14.29 and its 200-day moving average is $12.64. The company’s market cap is $545.9 million.

Flamel Technologies S.A. (NASDAQ:FLML) last issued its quarterly earnings data on Tuesday, July 29th. The company reported ($0.13) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.08) by $0.05. The company had revenue of $8.10 million for the quarter, compared to the consensus estimate of $9.92 million. During the same quarter in the prior year, the company posted ($1.29) earnings per share. On average, analysts predict that Flamel Technologies S.A. will post $-0.28 earnings per share for the current fiscal year.

Flamel Technologies SA has a pipeline of niche specialty pharmaceutical products. The Company’s drug delivery platforms are focused on developing safer, more efficacious formulations of drugs to address unmet medical needs.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.